BioWorld

June 10, 2009

Cancer Vaccine Firm 'Pique[s]' Investor Interest with Series A

CER called Game-Changer in Health Reform Debate

Tokai Prepares to Enter Clinic with Triple-Acting HRPC Drug

MDRNA Wins FDA OK for Calcitonin in Osteo

MDRNA Inc. is making good on its plan to maximize its shelved nasal programs, with the FDA's approval of a generic nasal spray for osteoporosis that has been launched by Par Pharmaceutical Cos. Inc. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

BioWorld

June 10, 2009

Cancer Vaccine Firm 'Pique[s]' Investor Interest with Series A

CER called Game-Changer in Health Reform Debate

Tokai Prepares to Enter Clinic with Triple-Acting HRPC Drug

Corrections & Clarifications

Other News To Note

Clinic Roundup

ADA Roundup

MDRNA Wins FDA OK for Calcitonin in Osteo

Today's news in brief

News in brief

Gene replacement rescues autism-related phenotypes in mice

For clonal hematopoiesis, epigenetics can be in driver’s seat

Elixiron’s enrupatinib shows upbeat interim phase II AD results